Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR
The Indian Council of Medical Research (ICMR) reports that 8,000 of 10,000 participants have enrolled in Phase 3 clinical trials for the indigenous tetravalent dengue vaccine, 'DengiAll'. The trial aims to test efficacy across all four circulating dengue serotypes in India.
Why it matters
Successful completion of these trials could provide India with its first licensed dengue vaccine, addressing a significant public health gap.
Following an announcement by the Indian Council of Medical Research (ICMR) and Panacea Biotec Limited to initiate third phase trials, about 8,000 of the targeted 10,000 participants have enrolled in the third phase of clinical trials for a dengue vaccine in India , Manoj Murhekar, Director, National Institute of Epidemiology, ICMR, Chennai, told The Hindu .
Factual reporting on clinical trial progress and government health initiatives.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in